关注
Mohamed E. Shaker
Mohamed E. Shaker
Professor of Pharmacology & Toxicology, Faculty of Pharmacy, Mansoura University
在 mans.edu.eg 的电子邮件经过验证
标题
引用次数
引用次数
年份
Comparison of imatinib, nilotinib and silymarin in the treatment of carbon tetrachloride-induced hepatic oxidative stress, injury and fibrosis
ME Shaker, KR Zalata, WZ Mehal, GE Shiha, TM Ibrahim
Toxicology and applied pharmacology 252 (2), 165-175, 2011
942011
Celastrol ameliorates murine colitis via modulating oxidative stress, inflammatory cytokines and intestinal homeostasis
ME Shaker, SA Ashamallah, ME Houssen
Chemico-Biological Interactions 210, 26-33, 2014
852014
Comparison of vitamin E, L-carnitine and melatonin in ameliorating carbon tetrachloride and diabetes induced hepatic oxidative stress
ME Shaker, ME Houssen, EM Abo-Hashem, TM Ibrahim
Journal of physiology and biochemistry 65, 225-233, 2009
662009
Nilotinib counteracts thioacetamide‐induced hepatic oxidative stress and attenuates liver fibrosis progression
ME Shaker, HA Salem, GE Shiha, TM Ibrahim
Fundamental & clinical pharmacology 25 (2), 248-257, 2011
642011
Nilotinib induces apoptosis and autophagic cell death of activated hepatic stellate cells via inhibition of histone deacetylases
ME Shaker, A Ghani, GE Shiha, TM Ibrahim, WZ Mehal
Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1833 (8), 1992-2003, 2013
602013
Modulation of carbon tetrachloride-induced hepatic oxidative stress, injury and fibrosis by olmesartan and omega-3
AA Shaaban, ME Shaker, KR Zalata, HA El-Kashef, TM Ibrahim
Chemico-biological interactions 207, 81-91, 2014
532014
Comparison of early treatment with low doses of nilotinib, imatinib and a clinically relevant dose of silymarin in thioacetamide-induced liver fibrosis
ME Shaker, GE Shiha, TM Ibrahim
European journal of pharmacology 670 (2-3), 593-600, 2011
482011
Therapeutic opportunities in damage-associated molecular pattern-driven metabolic diseases
I Garcia-Martinez, ME Shaker, WZ Mehal
Antioxidants & redox signaling 23 (17), 1305-1315, 2015
402015
The SMAC mimetic BV6 induces cell death and sensitizes different cell lines to TNF-α and TRAIL-induced apoptosis
M El-Mesery, ME Shaker, A Elgaml
Experimental Biology and Medicine 241 (18), 2015-2022, 2016
372016
Optimization and SAR investigation of novel 2, 3-dihydropyrazino [1, 2-a] indole-1, 4-dione derivatives as EGFR and BRAFV600E dual inhibitors with potent antiproliferative and …
HAM Gomaa, ME Shaker, SI Alzarea, OM Hendawy, FAM Mohamed, ...
Bioorganic Chemistry 120, 105616, 2022
292022
Clomiphene citrate co-treatment with low dose urinary FSH versus urinary FSH for clomiphene resistant PCOS: randomized controlled trial
ME Ghanem, LA Elboghdady, M Hassan, AS Helal, A Gibreel, M Houssen, ...
Journal of assisted reproduction and genetics 30, 1477-1485, 2013
292013
The novel TLR9 antagonist COV08-0064 protects from ischemia/reperfusion injury in non-steatotic and steatotic mice livers
ME Shaker, BN Trawick, WZ Mehal
Biochemical Pharmacology 112, 90-101, 2016
272016
Repression of acetaminophen-induced hepatotoxicity by a combination of celastrol and brilliant blue G
HA Abdelaziz, ME Shaker, MF Hamed, NM Gameil
Toxicology Letters, 6-18, 2017
252017
Inhibition of the JAK/STAT pathway by ruxolitinib ameliorates thioacetamide-induced hepatotoxicity
ME Shaker, SH Hazem, SA Ashamallah
Food and Chemical Toxicology 96, 290-301, 2016
242016
Nilotinib interferes with the signalling pathways implicated in acetaminophen hepatotoxicity
ME Shaker
Basic & clinical pharmacology & toxicology 114 (3), 263-270, 2014
212014
The novel Janus kinase inhibitor ruxolitinib confers protection against carbon tetrachloride-induced hepatotoxicity via multiple mechanisms
SH Hazem, ME Shaker, SA Ashamallah, TM Ibrahim
Chemico-biological interactions 220, 116-127, 2014
202014
Polymorphisms of glutathione S-transferase π 1 and toll-like receptors 2 and 9: Association with breast cancer susceptibility
MF Al‑Harras, ME Houssen, ME Shaker, K Farag, O Farouk, R Monir, ...
Oncology letters 11 (3), 2182-2188, 2016
192016
The selective c-Met inhibitor capmatinib offsets cisplatin-nephrotoxicity and doxorubicin-cardiotoxicity and improves their anticancer efficacies
ME Shaker, AA Shaaban, MM El-Shafey, ME El-Mesery
Toxicology and applied pharmacology 398, 115018, 2020
182020
A new CDK2 inhibitor with 3-hydrazonoindolin-2-one scaffold endowed with anti-breast cancer activity: Design, synthesis, biological evaluation, and in silico insights
MM Al-Sanea, AJ Obaidullah, ME Shaker, G Chilingaryan, MM Alanazi, ...
Molecules 26 (2), 412, 2021
152021
The c-Met inhibitor capmatinib alleviates acetaminophen-induced hepatotoxicity
KM Saad, ME Shaker, AA Shaaban, RS Abdelrahman, E Said
International Immunopharmacology 81, 106292, 2020
152020
系统目前无法执行此操作,请稍后再试。
文章 1–20